



# Disruption of the PDZ domain-binding motif of the dopamine transporter uniquely alters nanoscale distribution, dopamine homeostasis, and reward motivation

Received for publication, March 12, 2021, and in revised form, October 21, 2021. Published, Papers in Press, October 29, 2021.

<https://doi.org/10.1016/j.jbc.2021.101361>

Gunnar Sørensen<sup>1,2</sup>, Mattias Rickhag<sup>1</sup>, Damiana Leo<sup>3</sup> , Matthew D. Lycas<sup>1</sup>, Pernille Herrstedt Ridderstrøm<sup>2</sup>, Pia Weikop<sup>2</sup>, Jamila H. Lilja<sup>1</sup>, Pedro Rifes<sup>1</sup>, Freja Herborg<sup>1</sup>, David Woldbye<sup>1</sup>, Gitta Wörtwein<sup>2</sup> , Raul R. Gainetdinov<sup>4</sup>, Anders Fink-Jensen<sup>2</sup>, and Ulrik Gether<sup>1,\*</sup> 

From the <sup>1</sup>Department of Neuroscience, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; <sup>2</sup>Laboratory of Neuropsychiatry, Psychiatric Center Copenhagen, Mental Health Center & University of Copenhagen, Copenhagen, Denmark; <sup>3</sup>Neuroscience and Brain Technologies Department, Italian Institute of Technology, Genoa, Italy; <sup>4</sup>Institute of Translational Biomedicine and Saint-Petersburg University Hospital, Saint-Petersburg State University, Saint-Petersburg, Russia

Edited by Paul Fraser

The dopamine (DA) transporter (DAT) is part of a presynaptic multiprotein network involving interactions with scaffold proteins *via* its C-terminal PDZ domain-binding sequence. Using a mouse model expressing DAT with mutated PDZ-binding sequence (DAT-AAA), we previously demonstrated the importance of this binding sequence for striatal expression of DAT. Here, we show by application of direct stochastic reconstruction microscopy not only that the striatal level of transporter is reduced in DAT-AAA mice but also that the nanoscale distribution of this transporter is altered with a higher propensity of DAT-AAA to localize to irregular nanodomains in dopaminergic terminals. In parallel, we observe mesostriatal DA adaptations and changes in DA-related behaviors distinct from those seen in other genetic DAT mouse models. DA levels in the striatum are reduced to ~45% of that of WT, accompanied by elevated DA turnover. Nonetheless, fast-scan cyclic voltammetry recordings on striatal slices reveal a larger amplitude and prolonged clearance rate of evoked DA release in DAT-AAA mice compared with WT mice. Autoradiography and radioligand binding show reduced DA D2 receptor levels, whereas immunohistochemistry and autoradiography show unchanged DA D1 receptor levels. In behavioral experiments, we observe enhanced self-administration of liquid food under both a fixed ratio of one and progressive ratio schedule of reinforcement but a reduction compared with WT when using cocaine as reinforcer. In summary, our data demonstrate how disruption of PDZ domain interactions causes changes in DAT expression and its nanoscopic distribution that in turn alter DA clearance dynamics and related behaviors.

Dopamine (DA) plays a fundamental role as a modulatory neurotransmitter controlling locomotion, reward, cognition, and endocrine functions. Aberrant dopaminergic signaling is associated with neuropsychiatric diseases, such as schizophrenia, attention-deficit hyperactivity disorder, and drug addiction (1–3). The presynaptic DA transporter (DAT) is responsible for clearing released DA from the extracellular space and represents the major target for psychostimulants, such as cocaine and amphetamine (4–6). Importantly, the generation and characterization of genetically modified mice and rats with altered DAT expression have supported a pivotal role of DAT in regulating DA homeostasis. Mice and rats lacking DAT (DAT-KO) and mice with reduced DAT expression (DAT-knockdown [KD]) (7–9) exhibit profound alterations in extracellular DA dynamics with impaired DA clearance that lead to adaptive processes in the presynaptic and postsynaptic compartments (10, 11). The alterations in DA dynamics are, moreover, accompanied by critical behavioral changes (5, 7–9). Profound changes in DA dynamics have also been observed in knock-in (KI) mice expressing neuropsychiatric disease-associated DAT mutations (12, 13).

It is well established that the DA system, and in particular DA neurons projecting from the ventral tegmental area (VTA) to the nucleus accumbens, plays an essential role in addiction to drugs, such as cocaine, methamphetamine, heroin, and nicotine, that elicit major increases in extracellular nucleus accumbens DA levels through distinct pharmacological mechanisms (14). Abuse of alcohol and food has been linked to DA release as well, further supporting that shared mechanisms are likely to underlie the compulsive reward-seeking behavior seen in addicted individuals (14). In addition, there is compelling evidence suggesting that abuse promotes common adaptive changes in the DA system. A key finding in human studies, for example, is a marked decrease in striatal D2 receptor (D<sub>2</sub>R) binding, which is believed to result from repetitive and long-lasting stimulation of this high-affinity receptor

\* For correspondence: Ulrik Gether, [gether@sund.ku.dk](mailto:gether@sund.ku.dk).

Present address for Damiana Leo: Department of Neurosciences, University of Mons, Mons, Belgium.

## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes

leading to internalization and receptor downregulation (15–19). Indeed, the reduced D<sub>2</sub>R levels have been associated with a propensity for impulsive and compulsive behaviors and thus to be an important biomarker for the addicted brain (14). A decrease in the vesicular storage of presynaptic DA has furthermore been observed in human addicts, representing yet another key biological feature (19–23). However, although it is evident that alterations in D<sub>2</sub>R binding and striatal DA release might constitute interesting surrogate markers for the addicted brain (24–26), we still have a poor understanding of the mechanisms underlying these adaptations of the DA system and their precise biological effects.

We have generated a DAT KI mouse strain (DAT-AAA) with modified C terminus to investigate the significance of PDZ (PSD-95/Dlg/ZO-1) domain scaffold interactions for DAT function and DA homeostasis (27). In these mice, the C-terminal PDZ-target sequence (-LLV) has been substituted for three alanines (-AAA), resulting in abolished PDZ domain-mediated interactions that cause extensive loss of striatal DAT levels down to 10 to 20% of that seen in WT mice (27). Our data suggested that this loss is not caused by impaired folding and maturation of the protein but rather by enhanced degradation likely involving increased constitutive internalization of the transporter (27). An interesting question is whether this cellular phenotype also involves alteration in the nanoscopic distribution of the transporter. Indeed, our previous studies using super-resolution direct stochastic reconstruction microscopy (dSTORM) have revealed that in both cultured and brain slices, DAT is found to be sequestered into discrete phosphatidylinositol-4,5-bisphosphate-enriched nanodomains in the plasma membrane of presynaptic varicosities and neuronal projections (28, 29). These nanodomains were proposed to enable the neuron to rapidly move the transporter between different functional localizations and thereby optimize availability and activity of the transporter at nanoscale levels in the dopaminergic terminals (28, 29). Here, we apply super-resolution dSTORM to assess the nanoscale distribution of DAT in DAT-AAA mice as compared with WT mice in striatal slices. Importantly, the data show that both the WT and the DAT-AAA mutant are found in discrete nanodomains in dopaminergic terminals of the slices. The data moreover indicate that, despite lower expression, the DAT-AAA mutant is more prone to exist in these nanodomains than the WT transporter with a higher fraction of nanodomains >75 nm in diameter. Of major interest, we find that this altered nanoscale distribution of DAT-AAA, together with the decreased expression, is accompanied by unique homeostatic changes to the dopaminergic system that are distinct from those seen in other DAT genetic mouse models with reduced DA uptake capacity. We observe accordingly that, although the striatal DA levels are reduced in DAT-AAA mice to 45% of WT with a parallel increase in DA turnover, the amplitude of evoked DA release, as assessed by fast-scan cyclic voltammetry (FSCV) recordings from striatal slices, is markedly higher in DAT-AAA mice alongside with a prolonged clearance rate. Furthermore, we observe significant reduction in striatal D<sub>2</sub>R binding and striking changes in motivational

behavior including enhanced self-administration of liquid food but decreased self-administration of cocaine as compared with WT mice. In summary, the data substantiate the critical importance of presynaptic PDZ domain-mediated protein-protein interactions for proper temporal and spatial regulation of striatal DA homeostasis by DAT.

## Results


### Altered nanoscale distribution of DAT in DAT-AAA mice

We have recently shown by application of dSTORM that DAT distributes into cholesterol-dependent and phosphatidylinositol-4,5-bisphosphate-enriched nanodomains in the plasma membrane of presynaptic varicosities and neuronal projections of dopaminergic neurons (28, 29). To assess whether this nanoscale distribution of DAT was regulated by PDZ domain scaffold protein interactions, we decided to visualize DAT by dSTORM in striatal slices obtained from DAT-AAA mice and WT littermates. To identify dopaminergic terminals, we stained as well for the vesicular monoamine amine transporter 2 (VMAT2). The resulting reconstructed dSTORM images showed numerous irregular dopaminergic terminals/varicosities in slices from WT mice with both DAT and VMAT2 signal (Fig. 1A, top, example highlighted by yellow arrows). In slices from DAT-AAA mice, the number of DAT localizations was decreased, as expected, whereas the density and distribution of VMAT2 localizations were similar to that seen in the WT (Fig. 1, middle, example highlighted by yellow arrows). To validate that the DAT signal still was specific in the DAT-AAA mice, we performed a staining with and without the primary antibody MAB369. Importantly, background staining in the absence of primary antibody was very low and markedly lower than the DAT-AAA signal, supporting specificity of the DAT staining (Fig. S1).


To further assess the distribution in the dopaminergic terminals, we filtered the dSTORM images for likely dopaminergic presynaptic sites through an adaptation of Voronoi tessellation (30, 31) that we recently developed when analyzing DAT distribution in WT slices (29). In brief, DAT and VMAT2 signals were combined, and structures that were in the size range of varicosities and made up from localizations of a required density were isolated. By utilizing combined data from DAT and VMAT2 signals into this algorithm, presynaptic varicosities in both WT and DAT-AAA slices could be located (Fig. 1A, bottom). Dopaminergic presynaptic sites in the WT slices were often distinct by the occurrence of DAT in a clustered distribution adjacent to the VMAT2 signal (Fig. 1A), similar to what we have observed before in cultured DA neurons (28). In the DAT-AAA slices, there were far fewer DAT localizations compared with WT present on the presynaptic varicosities; however, the signal appeared to be highly clustered and often adjacent to the VMAT2 signal (Fig. 1A, bottom).

Previous EM data have demonstrated that essentially all WT DATs in striatal dopaminergic varicosities resides in the plasma membrane (32). To ascertain that DAT-AAA also


A



B



C



**Figure 1. Visualization of DAT by super-resolution dSTORM imaging in striatal slices shows evidence for a hyperclustered phenotype of DAT-AAA.** A, example of dual color dSTORM images for DAT (white) and VMAT2 (green) from the striatum of a WT mouse and a DAT-AAA mouse. Top panel, WT mouse striatal section (left) with region of interest (white box) shown in the other images; middle left, merged DAT and VMAT2 signal; middle right, DAT signal; right, VMAT2 signal. Middle panel, DAT-AAA mouse striatal section (left) with region of interest (white box) shown in the other images; middle left, merged DAT and VMAT2 signal; middle right, DAT signal; right, VMAT2 signal. Lower panel, example of WT and DAT-AAA images before (left and middle right) and after filtering (middle left and right) for dopaminergic terminals/varicosities (see Experimental procedures section). Yellow arrows indicate



## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes

resided primarily in the plasma membrane of the varicosities, we took advantage of the low frequency of localizations in the DAT-AAA dataset. This made possible to determine the 3D position of each localization by fitting the point-spread function to an elliptical gaussian. For each identified varicosity, a 3D convex hull was computed for the combination of DAT and VMAT2 localizations. The distance from every single localization was measured to this hull and recorded as to whether it was for DAT or for VMAT2 (Fig. S2). Indeed, the majority of DAT-AAA localizations resided markedly closer to the likely localization of the plasma membrane (the convex hull) than the obligate intracellular VMAT2 localizations (Fig. S2). Because the VMAT2 is localized in cytosol on synaptic vesicles that predictably would be close to the plasma membrane, the data support that the DAT-AAA localizations identified for the most part resides in the plasma membrane and not in an intracellular compartment. It is even likely that much of the DAT-AAA signal that we detect away from the surface hull of the varicosity is arising from the lack of z resolution in general. Unfortunately, the same analysis could not reliably be done on WT because of the much higher density of localizations detected (see legend to Fig. S2 for details).

Analysis of our data by density-based spatial clustering of applications with noise (DBSCAN) (28, 33) substantiated clustering of DAT into irregular nanodomains in dopaminergic terminals from both WT and DAT-AAA mice (Fig. 1, B and C). We decided to analyze the clusters in two ways. First, we assessed a possible difference in cluster size by arbitrarily calculating clusters that were larger than 75 nm in diameter. Interestingly, despite the reduced level of DAT in DAT-AAA slices, there was a greater proportion of large (>75 nm in diameter) transporter clusters for DAT-AAA as compared with WT (Fig. 1B). This was particularly evident on apparent varicosities with fewer localizations (Fig. 1B). Second, we determined the fraction of DAT localizations present in dense clusters, which not surprisingly showed that overall, there was a greater fraction of WT DAT localizations found in dense clusters (Fig. 1C). This likely reflected the increased amount of DAT found on a given varicosity because when separated by the number of DAT localizations found on a given varicosity, there were more DAT-AAA localizations found within dense clusters than in comparable WT varicosities (Fig. 1C). That is, the fraction of localizations in nanodomains was higher at comparable densities between DAT-AAA and WT (*red dots versus black dots*; Fig. 1B), indicating a higher propensity for DAT-AAA to be present within a nanodomain. Thus,

disruption of the C-terminal PDZ-binding sequence of DAT does not only dramatically reduce expression of the transporter but also leads to increased clustering into nanodomains of the remaining DAT in dopaminergic terminals of the striatum.

### Decreased DA tissue content in DAT-AAA mice

Next, we assessed possible alterations in DA homeostasis occurring as a result of the reduced striatal DAT expression together with the apparent change in nanoscale distribution of DAT in DAT-AAA mice as described previously. We determined total striatal tissue content of DA and DA metabolites (Fig. 2A). The analysis of the striatal homogenates revealed a decrease in total DA levels in the DAT-AAA mice to ~45% of WT (WT,  $3.8 \pm 0.3$   $\mu\text{g/g}$  tissue; DAT-AAA,  $1.68 \pm 0.14$   $\mu\text{g/g}$  tissue,  $p < 0.0001$ ) but increased homovanillic acid (HVA) concentrations (WT,  $0.71 \pm 0.04$   $\mu\text{g/g}$  tissue; DAT-AAA,  $1.48 \pm 0.12$   $\mu\text{g/g}$  tissue,  $p < 0.0001$ ) as compared with WT. There was no difference in 3,4-dihydroxyphenylacetic acid (DOPAC) levels (WT,  $0.73 \pm 0.12$   $\mu\text{g/g}$  tissue; DAT-AAA,  $0.6 \pm 0.07$   $\mu\text{g/g}$  tissue,  $p > 0.05$ , Fig. 2A). However, both the HVA/DA ratio (~4.8-fold,  $p < 0.0001$ ) and the DOPAC/DA ratio (~1.8-fold,  $p < 0.05$ ) were significantly increased, indicating increased DA turnover in DAT-AAA mice (Fig. 2B).


### Enhanced evoked release and prolonged clearance of DA in DAT-AAA mice

To investigate the dynamics of vesicular DA release and reuptake, we performed FSCV recordings on striatal brain slices. Interestingly, in the slices derived from DAT-AAA mice, we observed elevated peak concentrations of DA (~7.5-fold higher than WT) after stimulated release (WT,  $0.072 \pm 0.025$   $\mu\text{M}$ ; DAT-AAA,  $0.544 \pm 0.27$   $\mu\text{M}$ ,  $p < 0.05$ ) (Fig. 3, A and B). Consistent with the markedly reduced DAT levels, the data moreover revealed substantially prolonged clearance (approximately fourfold longer) of DA in DAT-AAA mice as compared with WT (WT,  $\tau = 0.62 \pm 0.06$ ; DAT-AAA,  $\tau = 2.4 \pm 2.8$ ,  $p < 0.05$ , Fig. 3C).

We next addressed possible changes in presynaptic D<sub>2</sub>R autoreceptor function as impaired autoreceptor function could contribute to the elevated levels of released DA in the DAT-AAA mice. Accordingly, we determined by FSCV the effect of the D<sub>2</sub>R agonist quinpirole on stimulated DA release. In both DAT-AAA mice and WT mice, quinpirole blocked DA

---

examples of presumed dopaminergic terminals/varicosities. B, example of WT varicosity (*left*) and DAT-AAA varicosity (*middle left*), where clusters were identified with DBSCAN parameters 15 nm search radius and five number of points. Clusters with diameter >75 nm are colored in *green*, and remaining clusters are colored in *magenta*. Despite fewer DAT localizations for DAT-AAA, there is a larger fraction of clusters with diameter >75 nm. Quantification of the data is shown as fraction of nanodomains >75 nm (mean  $\pm$  SE, unpaired *t* test:  $p < 0.0001$ ) (*middle panel*) and as a comparison of the fraction of clusters identified with a diameter >75 nm and the number of localizations found in each detected varicosity (WT, *gray dots*; DAT-AAA, *red dots*). C, example of WT varicosity (*left*) and DAT-AAA varicosity (*middle left*) comparing number of DAT localizations per varicosity that are present in dense clusters (identified with DBSCAN parameters 25 nm search radius and 30 number of points, shown in *blue*). Quantification of the data is shown as fraction of localizations found within large dense clusters (mean  $\pm$  SE, unpaired *t* test:  $p < 0.0001$ ) (*middle panel*) and as a comparison of the number of localizations found in each detected varicosity with the fraction of DAT localizations found within large dense clusters. Despite fewer localizations for DAT detected in the DAT-AAA varicosities (*red dots*), more large dense clusters were observed than in WT varicosities (*gray dots*) with equivalent number of localizations. Data are from 4473 WT varicosities and 1186 DAT-AAA varicosities from 30 dSTORM images taken from three animals for each condition. DAT, dopamine transporter; DBSCAN, density-based spatial clustering of applications with noise; dSTORM, direct stochastic reconstruction microscopy; VMAT2, vesicular monoamine amine transporter 2.



**Figure 2. Striatal tissue content of DA and metabolites.** A, total tissue content of DA and major metabolites in striatal homogenates from DAT-AAA and WT mice. The content of DA was significantly decreased (~45% of WT) in the DAT-AAA mice, whereas the content of HVA was significantly increased (approximately twofold). Data are shown as means  $\pm$  SE (WT:  $n = 8$ ; DAT-AAA:  $n = 9$ ), \*\*\*\* $p < 0.0001$ , DAT-AAA versus corresponding WT group, Holm-Sidak post hoc test after two-way ANOVA (significant effect of metabolite and genotype,  $F_{(4,75)} = 165.7$ ,  $p < 0.0001$  and  $F_{(1,75)} = 15.93$ ,  $p = 0.0002$ , respectively). B, DOPAC/DA and HVA/DA turnover ratios. DAT-AAA animals displayed not only a 1.8-fold increased DOPAC/DA ratio indicative of increased DA synthesis but also a 4.8-fold increased HVA/DA ratios indicative of an increased turnover of DA. Data are shown as means  $\pm$  SE (WT:  $n = 8$ ; DAT-AAA:  $n = 9$ ), \* $p < 0.05$ , \*\*\*\* $p < 0.0001$ , Holm-Sidak post hoc test after two-way ANOVA (significant effect of ratio and genotype,  $F_{(1,30)} = 25.97$ ,  $p < 0.0001$  and  $F_{(1,30)} = 72.28$ ,  $p < 0.0001$ , respectively). DA, dopamine; DAT, dopamine transporter; DOPAC, dihydroxyphenylacetic acid; HVA, homovanillic acid.

release, supporting preserved  $D_2R$  autoreceptor function in DAT-AAA mice (Fig. 3D).

**Unaltered  $D_1$  receptor immunoreactivity and binding sites in DAT-AAA mice**

To investigate the cellular/regional distribution of the  $D_1$  receptor ( $D_1R$ ) in DAT-AAA and WT mice, we determined  $D_1R$ -immunoreactivity ( $D_1R$ -ir) in the mesostriatal dopaminergic system. Dense  $D_1R$ -ir was observed in dorsal/ventral striatum, substantia nigra, and VTA as well as olfactory tubercles. DAT-AAA mice showed similar intensities of  $D_1R$ -ir in both striatal and midbrain areas compared with WT mice, thus suggesting unaltered expression of the receptor (Fig. 4A). In midbrain,  $D_1R$  distribution was predominant in the substantia nigra pars reticulata, but again, no difference was observed between genotypes (Fig. 4B). Importantly, the observed  $D_1R$  distribution was in accordance with earlier reports (34).

In addition to immunohistochemical localization of the  $D_1R$ , we assessed functional binding sites in striatum using quantitative autoradiography. Binding of the tritiated  $D_1R$  antagonist [ $^3H$ ]-SCH23390 was determined in sections from both WT and DAT-AAA mice revealing a high density of  $D_1R$ -binding sites in dorsal and ventral striatum as well as in the midbrain with no difference between the genotypes (dorsal striatum: WT,  $1288 \pm 73$  Bq/mg tissue, DAT-AAA,  $1234 \pm 67$  Bq/mg tissue,  $p = 0.60$ ; ventral striatum: WT,  $914 \pm 40$  Bq/mg tissue; DAT-AAA,  $833 \pm 37$  Bq/mg tissue,  $p = 0.32$ ; midbrain: WT,  $1565 \pm 134$  Bq/mg tissue, DAT-AAA,  $1168 \pm 141$  Bq/mg tissue,  $p = 0.21$ , Fig. 4, C and D).

**Reduced  $DA D_2R$  binding sites in the striatum of DAT-AAA mice**

We also performed quantitative autoradiography for  $D_2R$  by using the tritiated  $D_2R$  antagonist [ $^3H$ ]-raclopride. In WT mice, we observed a high density of  $D_2R$  binding sites in dorsal and ventral striatum. In DAT-AAA mice, however, [ $^3H$ ]-raclopride binding was reduced in both regions with the most prominent reduction in the dorsal striatum (dorsal striatum: WT,  $912 \pm 52$  Bq/mg tissue and DAT-AAA,  $566 \pm 29$  Bq/mg tissue,  $p < 0.001$ ; ventral striatum: WT,  $446 \pm 30$  Bq/mg tissue and DAT-AAA,  $366 \pm 14$  Bq/mg tissue,  $p < 0.05$ , Fig. 4, E and F). Of note, we were unable to detect any specific [ $^3H$ ]-raclopride binding in the midbrain.

To substantiate the reduced binding of [ $^3H$ ]-raclopride in the striatum, we examined the density of  $D_2R$  in striatal membranes in a [ $^3H$ ]-raclopride saturation binding experiment (Fig. 4G). In full agreement with the autoradiography data, the maximal number of binding sites ( $B_{max}$ ) was significantly reduced in DAT-AAA compared with WT mice ( $B_{max}$ ,  $68 \pm 10\%$  of WT,  $p < 0.05$ ) (Fig. 4H) without altered  $K_d$  ( $K_d$  DAT-AAA,  $1.34 \pm 0.14$  nM;  $K_d$  WT,  $1.12 \pm 0.19$  nM,  $p > 0.05$ ).


**Unchanged  $D_1R$  and  $D_2R$  transcriptions in DAT-AAA mice**

To assess whether there were any adaptive changes of the genes encoding  $D_1R$  (*Drd1*) and  $D_2R$  (*Drd2*) transcription, we performed real-time quantitative RT-PCR (qRT-PCR) on mRNA isolated from the midbrain and striata of WT and DAT-AAA mice. We dissected both ventral midbrain and striatum to obtain mRNA from (i) the dopaminergic neurons (presynaptic expression) and (ii) the striatum to obtain mRNA primarily from striatal neurons (postsynaptic expression). In the midbrain, the qRT-PCR  $D_1R$  signal was low relative to our control region (cerebellum), and it was similar in WT and DAT-AAA mice (Fig. S3). For  $D_2R$ , we observed a much stronger signal that also did not differ between WT and DAT-AAA mice (Fig. S3). Even stronger signals were observed for both receptors in the striatum consistent with high expression in striatal neurons. In the DAT-AAA mice, there was a trend for both  $D_1R$  and  $D_2R$  toward a decrease, as compared with WT mice, but the difference was not significant (Fig. S3). Thus, despite a reduction in  $D_2R$  binding, there was no reduction of  $D_2R$  transcription in the DAT-AAA mice, suggesting that the receptor may be subject to increased agonist-induced internalization and increased protein turnover.

**Increased liquid food self-administration in DAT-AAA mice**

Next, we wanted to investigate how the altered DA homeostasis in DAT-AAA mice affected DA-related behaviors. Because reduced  $D_2R$  levels (15–19) and a reduced pool of DA (19–23) have been strongly associated with impulsive and compulsive behaviors related to addiction including binge eating, naive DAT-AAA and WT mice were evaluated in a palatable liquid food self-administration paradigm. The self-administration was assessed both under a fixed ratio of one (FR1) and progressive ratio (PR) schedule of reinforcement (Fig. 5). Under the FR1 schedule, both genotypes demonstrated

## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes



**Figure 3. Enhanced vesicular DA release and prolonged clearance rate of extracellular DA in DAT-AAA mice.** A, DAT-AAA mice show an increase in evoked DA release in striatal slices as measured by fast-scan cyclic voltammetry. *Left*, representative stimulated DA release shown (DAT-AAA, red; WT, black), *Right*, color plots displaying sequential voltammograms indicating larger and more prolonged increase in DA levels for DAT-AAA (*lower panel*) than for WT (*upper panel*) (time in seconds, x-axis; applied voltage, y-axis; z-axis; measured current in color). B, peak concentrations of DA following stimulated response in striatal slices show elevated DA levels. Data are shown as means  $\pm$  SE of measurements on 45 slices from seven WT mice and on 55 slices from seven DAT-AAA mice;  $*p < 0.05$ , Wilcoxon matched-pairs signed rank test. C, clearance of DA is prolonged in DAT-AAA mice. Data are presented as tau,  $*p < 0.05$ , Student's *t* test. D, dose-response treatment using the  $D_2$ R-agonist quinpirole shows blockade of stimulated DA release as measured by fast-scan cyclic voltammetry in striatal slices. Data are shown as means  $\pm$  SE, WT,  $n = 10$ ; DAT-AAA,  $n = 7$ . DA, dopamine; DAT, dopamine transporter.


liquid food intake that increased significantly with increasing concentrations of palatable liquid food (Fig. 5A). There was a significant effect of both food concentration and genotype (two-way ANOVA:  $F_{(4,65)} = 20.35$ ,  $p < 0.0001$  and  $F_{(1,65)} = 12.90$ ,  $p = 0.0006$ ;  $p < 0.001$ , respectively). Notably, post hoc analysis showed an increased response rate in DAT-AAA mice at 10% of liquid food compared with WT mice ( $p < 0.05$ ). Under the PR schedule, there was also a significant effect of palatable liquid food concentration (two-way ANOVA:  $F_{(4,60)} = 14.53$ ;  $p < 0.001$ ) and significant effect of genotype ( $F_{(1,60)} = 38.94$ ;  $p < 0.001$ ) with no genotype by food concentration interaction ( $F_{(4,60)} = 0.54$ ,  $p = 0.70$ ). Post hoc analysis showed that DAT-AAA mice reached significantly higher breaking points at 3, 10, 32, and 100% of liquid food compared with WT mice ( $p < 0.05$  and  $p < 0.01$ ) (Fig. 5B).

Together, the data show that DAT-AAA mice are willing to work harder for a food reward than WT mice.

### Attenuated cocaine self-administration in DAT-AAA mice

We next evaluated whether DAT-AAA mice also would show increased motivation to self-administer cocaine or whether the dramatic reduction in expression and distribution of its main target, DAT, would affect the pharmacological action of cocaine. The mice were tested under both FR1 and PR schedules. Strikingly, DAT-AAA mice did not self-administer cocaine ( $p = 0.76$ ), whereas WT mice did. Under the FR schedule, there was a significant effect of cocaine dose (two-way ANOVA:  $F_{(4,80)} = 2.76$ ;  $p = 0.03$ ) and a significant effect of genotype ( $F_{(1,80)} = 4.38$ ;  $p = 0.04$ ) with no genotype by






**Figure 4. DA receptor expression and binding sites in DAT-AAA and WT mice.** *A* and *B*, representative photomicrographs show similar D<sub>1</sub>R immunoreactivity (D<sub>1</sub>R-ir) in striatum of WT and DAT-AAA mice (*A*) and ventral midbrain (*B*). In striatum, dense D<sub>1</sub>R-ir was observed particularly in the dorsal part, whereas less D<sub>1</sub>R-ir was seen in ventral striatum (scale bars represent 500 μm). *C* and *D*, assessment of functional D<sub>1</sub>R-binding sites was investigated using quantitative autoradiography. [<sup>3</sup>H]-SCH23390, a selective D<sub>1</sub>R ligand, revealed a high density of D<sub>1</sub>R-binding sites in the striatum and midbrain with similar intensities in both genotypes. Data are specific [<sup>3</sup>H]-SCH23390 binding in Bq/mg, means ± SE, n = 5 (dorsal striatum: WT, 1288 ± 73 Bq/mg tissue; DAT-AAA, 1234 ± 67 Bq/mg tissue, *p* = 0.60; ventral striatum: WT, 914 ± 40 Bq/mg tissue; DAT-AAA, 833 ± 37 Bq/mg tissue, *p* = 0.32, midbrain: WT, 1565 ± 134 Bq/mg tissue; DAT-AAA, 1168 ± 141 Bq/mg tissue, *p* = 0.21, multiple *t* tests with Holm–Sidak correction) (scale bars represent 1 mm). *E* and *F*, assessment of functional D<sub>2</sub>R-binding sites was investigated using quantitative autoradiography. [<sup>3</sup>H]-Raclopride, a selective D<sub>2</sub>R ligand, revealed high density of D<sub>2</sub>R-binding sites in the striatum of both WT and DAT-AAA mice; however, there was a significant reduction in binding in both the dorsal (DStr) and ventral striatum (VStr) of DAT-AAA mice. Data are [<sup>3</sup>H]-raclopride binding in Bq/mg, means ± SE, n = 5 (dorsal striatum: WT, 912 ± 52 Bq/mg tissue; DAT-AAA, 566 ± 29 Bq/mg tissue, \*\*\**p* < 0.001; ventral striatum: WT, 446 ± 30 Bq/mg tissue; DAT-AAA, 366 ± 14 Bq/mg tissue, \**p* < 0.05, multiple *t* tests with Holm–Sidak correction) (scale bar represents 1 mm). No binding could be detected in the midbrain. *G*, saturation radioligand binding experiments on striatal membranes using [<sup>3</sup>H]-raclopride, a D<sub>2</sub>R antagonist. Compiled normalized saturation curves demonstrate significantly reduced number of binding sites in striatum from DAT-AAA mice compared with WT. Data are shown as means ± SE, n = 4 in percent of the B<sub>max</sub> for WT (206 ± 25 fmol/mg protein). Equilibrium dissociation constant (K<sub>d</sub>) was not significantly different between the genotypes (K<sub>d</sub>: WT, 1.12 ± 0.19 nM; DAT-AAA, 1.34 ± 0.14 nM [n = 4]). *H*, B<sub>max</sub> for DAT-AAA in percent of B<sub>max</sub> for WT. Data are shown as means ± SE, n = 4, \**p* < 0.05, one-sample *t* test. The average total counts (cpm) for 8 nM [<sup>3</sup>H]-raclopride binding were WT, 1195 ± 211; DAT-AAA, 875 ± 91. The average counts (cpm) for nonspecific binding of 8 nM [<sup>3</sup>H]-raclopride were: WT, 371 ± 95 cpm; DAT-AAA, 294 ± 27. All data are shown as means ± SE. DA, dopamine; DAT, dopamine transporter.

dose interaction ( $F_{(4,80)} = 1.79$ ,  $p = 0.14$ ). Post hoc analysis indicated that DAT-AAA mice responded with significantly fewer nose pokes at 0.32 mg/kg/infusion ( $p < 0.05$ ) of cocaine compared with WT mice (Fig. 6A). Similarly, under the PR schedule of reinforcement, two-way ANOVA revealed a significant effect of cocaine dose (two-way ANOVA:  $F_{(4,25)} = 9.32$ ;  $p < 0.001$ ) and a significant effect of genotype ( $F_{(1,25)} = 10.78$ ;  $p = 0.0030$ ) with no genotype by dose interaction ( $F_{(4,25)} = 2.47$ ;  $p = 0.07$ ) (Fig. 6B). Holm–Sidak post hoc analysis showed that DAT-AAA mice responded with significantly fewer nose pokes at 3.2 mg/kg/infusion ( $p < 0.01$ ) of cocaine compared with

WT mice (Fig. 6B). Thus, the pharmacological effect of cocaine appeared clearly hampered in DAT-AAA mice.


This was further supported by data from *in vivo* microdialysis experiments showing that administration of cocaine (30 mg/kg) resulted in an expected large increase in extracellular DA levels in WT mice. The increase peaked at  $415 \pm 48\%$  of basal level 40 min following injection before it gradually declined. In DAT-AAA mice, however, we observed an attenuated response to cocaine compared with WT mice with DA levels peaking at  $184 \pm 24\%$  of basal level 60 min after injection (Fig. 7A). A three-way repeated-measures ANOVA

## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes





**Figure 5. Operant self-administration of liquid food reinforcements.** Food-maintained operant behavior under FR1 (A) and the PR (B) schedule of reinforcement in DAT-AAA and WT. A, DAT-AAA showed a higher number of nose pokes than WT mice in food-maintained responding under the FR1 schedule. Data are shown as means  $\pm$  SE, WT,  $n = 7$ , DAT-AAA,  $n = 8$ ,  $*p < 0.05$ , DAT-AAA versus WT group, Holm-Sidak post hoc test following two-way ANOVA (significant effect of food concentration and genotype,  $F_{(4,65)} = 20.35$ ,  $p < 0.0001$  and  $F_{(1,65)} = 12.90$ ,  $p = 0.0006$ , respectively). B, under the PR schedule of reinforcement, DAT-AAA mice reached higher breaking points at a concentration of 3, 10, 32, and 100% liquid food. Data are shown as means  $\pm$  SE,  $n = 7$ ,  $**p < 0.01$ ,  $*p < 0.05$ , DAT-AAA versus WT group, WT; Holm-Sidak post hoc test following two-way ANOVA (significant effect of liquid food concentration and genotype,  $F_{(4,60)} = 14.53$ ;  $p < 0.001$  and  $F_{(1,60)} = 38.94$ ;  $p < 0.001$ , respectively, with no genotype by food concentration interaction,  $F_{(4,60)} = 0.54$ ,  $p = 0.70$ ). DAT, dopamine transporter; FR1, fixed ratio of one; PR, progressive ratio.

showed a significant effect of genotype ( $F_{(1,12)} = 48.76$ ,  $p < 0.0001$ ), time ( $F_{(9,108)} = 26.93$ ,  $p < 0.0001$ ), and cocaine treatment ( $F_{(1,12)} = 92.09$ ,  $p < 0.0001$ ). Post hoc analysis showed that cocaine treatment was associated with a



**Figure 6. Operant self-administration of cocaine.** Cocaine-maintained operant behavior under the FR1 (A) and the PR (B) schedule of reinforcement in DAT-AAA and WT mice. A, DAT-AAA mice showed an attenuated response compared with WT mice in cocaine-maintained response under the FR1 schedule. Data are shown as means  $\pm$  SE,  $n = 9$ ,  $*p < 0.05$ , DAT-AAA versus WT, Holm-Sidak post hoc test following two-way ANOVA (significant effect of cocaine dose and genotype,  $F_{(4,80)} = 2.76$ ;  $p = 0.03$  and  $F_{(1,80)} = 4.38$ ;  $p = 0.04$ , respectively, with no genotype by dose interaction,  $F_{(4,80)} = 1.79$ ,  $p = 0.14$ ). B, DAT-AAA mice showed an attenuated response compared with WT mice in cocaine-maintained response under the PR schedule. Data are shown as means  $\pm$  SE,  $n = 4$ ,  $**p < 0.01$ , DAT-AAA versus WT, Holm-Sidak post hoc test following two-way ANOVA (significant effect of cocaine dose and genotype,  $F_{(4,25)} = 9.32$ ;  $p < 0.001$  and  $F_{(1,25)} = 10.78$ ;  $p = 0.0030$ , respectively, with no genotype by dose interaction,  $F_{(4,25)} = 2.47$ ;  $p = 0.07$ ). DAT, dopamine transporter; FR1, fixed ratio of one; PR, progressive ratio.



**Figure 7. Effects of cocaine on extracellular DA levels and locomotion.** A, effect of cocaine (30 mg/kg s.c.) or saline on extracellular DA levels measured by microdialysis (fractions of 20 min) in the dorsal striatum of freely moving WT (A) or DAT-AAA mice. Extracellular DA levels increased fourfold in WT mice after cocaine administration, whereas DAT-AAA mice only displayed  $\sim 1.8$ -fold increase in extracellular DA levels. Data are shown as means  $\pm$  SE (WT,  $n = 6$ ; DAT-AAA,  $n = 8$ ).  $****p < 0.0001$ ,  $**p < 0.01$ , genotype effect (WT versus DAT-AAA mice) after three-way ANOVA and Holm-Sidak post hoc test (cocaine treatment:  $F_{(1,12)} = 92.09$ ;  $p < 0.0001$ ). B, effect of cocaine on locomotor activity in DAT-AAA and WT mice. The locomotion test of 1 h shows impaired response to cocaine (30 mg/kg) in DAT-AAA as compared with WT. Data are shown as means  $\pm$  SE; DAT-AAA,  $n = 8$ ; WT,  $n = 9$ ,  $***p < 0.001$ , cocaine (30 mg/kg i.p.) versus saline for WT (no significance for DAT-AAA,  $p = 0.35$ ), Holm-Sidak post hoc analysis test after two-way ANOVA (significant effect of cocaine treatment,  $F_{(1,33)} = 20.38$ ;  $p < 0.001$ , but no significant effect of genotype,  $F_{(1,33)} = 0.77$ ;  $p = 0.39$ ). DA, dopamine; DAT, dopamine transporter; s.c., subcutaneously.

significant genotype effect (WT versus DAT-AAA) at multiple time points (20–100 min following cocaine treatment,  $p < 0.01$ – $0.0001$ ; Fig. 7A). Overall, the data demonstrate that administration of a dose of cocaine (30 mg/kg subcutaneously [s.c.]) elicited a fourfold increase in extracellular DA levels in WT mice, which was significantly attenuated in the DAT-AAA mice.

We finally assessed whether the effect of cocaine on locomotor activity in DAT-AAA mice was affected as well. Indeed, the locomotion test of 1 h revealed that alanine substitutions of the C-terminal PDZ domain in DAT-AAA mice were associated with a dampened response to cocaine (significant genotype  $\times$  dose interaction in a two-way ANOVA:  $F_{(1,33)} = 6.41$ ;  $p < 0.05$ ; Fig. 7B). A two-way ANOVA showed a significant effect of cocaine treatment (two-way ANOVA:  $F_{(1,33)} = 20.38$ ;  $p < 0.001$ ) but no significant effect of genotype ( $F_{(1,33)} = 0.77$ ;  $p = 0.39$ ). Holm-Sidak post hoc analysis



showed that cocaine (30 mg/kg i.p.) increased locomotor activity in WT mice ( $p < 0.001$ ) but did not have any effect in DAT-AAA mice compared with saline groups (Fig. 7B).

## Discussion

Presynaptic DAT sequesters released DA from the synapse and plays a major role in controlling DA homeostasis. We have previously reported that the C-terminal PDZ domain-binding sequence of DAT is required for proper targeting and membrane stabilization of DAT in striatal terminals (27). Here, we show that distinct adaptations of the mesostriatal DA system may occur as a consequence of reduced striatal DAT levels concomitant with an altered nanoscopic distribution of the transporter. Thus, the data substantiate the unequivocal importance of preserved PDZ domain interactions for proper DAT function and distribution, while at the same time revealing striking changes to the DA system.

We have earlier reported by employment of super-resolution microscopy that DAT distributes into nanodomains in varicosities/boutons of DA neurons. Our previous data suggested that the nanodomains consist of 10s of DAT molecules and that DAT preferentially assumes an inward facing conformation within these domains (28, 29). The data also suggested that localization of DAT to nanodomains was tightly regulated; that is, while DA D<sub>2</sub> autoreceptor activity promoted nanodomain localization, both acute and sustained membrane depolarization caused dispersal of DAT nanodomains. It was therefore speculated that DAT nanodomain distribution represents a means by which DA neurons can temporally and spatially switch DAT between distinct functional states to enable optimal availability of the transporter (28, 29). Such speculations are in line with recent findings for other neuronal membrane proteins, including ion channels and receptors for which dynamic sequestering into nanoclusters is believed to be central for cellular function (see, e.g., (35)).

In slices from DAT-AAA mice, we found, as expected, that the dSTORM DAT signal in the individual terminals/varicosities was much lower as compared with WT, yet the signal was still highly clustered and distributed into nanodomains. According to our analysis of thousands of terminals/varicosities, allowing for comparison of varicosities with similar levels of DAT in both DAT-AAA mice and WT mice, it appeared that the DAT-AAA mutant showed a higher propensity to be localized in nanodomains and that the fraction of larger nanodomains (>75 nm) was higher in slices from DAT-AAA mice than from WT mice. This suggests that unclustered DAT, rather than clustered nanodomain-localized DAT, interacts with still unknown PDZ domain proteins, and that these interactions promote the localization of DAT outside its nanodomain distribution. An interesting consideration would be that breaking these interactions would not only increase nanodomain localization but also the constitutive internalization and degradation that we have reported for DAT-AAA (28). Indeed, membrane microdomains have previously been suggested to serve as “hot spots” for DAT internalization (36).

It could therefore also be considered whether DAT-AAA resided more intracellularly in the dopaminergic varicosities and thus that the observed apparent change in nanodomain localization in part might reflect redistribution of DAT-AAA away from the membrane. However, a quantitative analysis systematically comparing dSTORM detected DAT-AAA localizations with those of VMAT2 in single varicosities strongly pointed to preserved surface localization of DAT-AAA. Unfortunately, we could not reliably carry out the same analysis for WT because of the much higher density of localizations detected (see legend to Fig. S2 for details). Nevertheless, although the precise molecular processes remain to be determined, our data add strong support for the existence of still poorly understood nanoscopic regulatory mechanisms with biological implications for the spatial and temporal functions of DAT and consequently for DA homeostasis.

The neuroadaptive changes in the DA system of DAT-AAA mice are, according to our data, different from those seen in other DAT mutant mouse models. We observed, using FSCV recordings in striatal slices, that evoked DA release in slices from DAT-AAA mice resulted in higher DA peak values with much slower DA clearance as compared with slices from WT mice. This result is different from findings for DAT-KO mice, where evoked DA release also revealed slower clearance but DA peak levels that were substantially lower and corresponding to only ~25% of the values observed for WT mice (7, 8). We would argue, that the lower peak DA levels, as compared with WT mice, would be expected in DAT-KO mice having only ~5% of the total striatal DA tissue level seen in WT mice (11). In contrast, DAT-AAA mice maintain a relatively large DA pool (~45% of WT levels), which not only suggests that even rather low reuptake capacity is sufficient to maintain a reasonable DA pool but also explain the DA “overshoot” as compared with WT, that is, a pool that is nearly half of that seen in WT combined with reuptake capacity only 10 to 20% of WT would be predicted to result in larger DA peak levels. In this context, it is somewhat surprising that FSCV experiments on slices for DAT-KD with 10% residual uptake capacity show markedly reduced peak DA levels compared with WT (8). Thus, despite reported similar uptake capacities, DAT-KD and DAT-AAA mice display differences in DA homeostasis. It is conceivable that these differences are related to the nature of the two transgenic mouse models; that is, whereas the reduction in uptake in DAT-KD mice is a direct result of reduced transcriptional activity, the reduced capacity in DAT-AAA mice is the complex result of disrupted PDZ domain interactions, leading to altered nanoscopic distribution and turnover of the transporter. We can at the present stage mainly speculate on how exactly these changes affect spatiotemporal DAT function, yet they still provide a possible explanation for the apparent differences between the models.

In the DAT-AAA mice, we also observed interesting adaptive changes characterized by reduced striatal D<sub>2</sub>R binding with no change in D<sub>1</sub>R binding. Interestingly, transcriptional analysis by qRT-PCR revealed no changes for either receptor, supporting selective downregulation of D<sub>2</sub>R in striatum as a

## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes

likely result of increased agonist-induced internalization and increased protein turnover. Notably, D<sub>2</sub>Rs have higher DA affinity and are therefore possibly more prone to down-regulation than D<sub>1</sub>Rs (37). Our findings for DAT-AAA differ from those in DAT-KO and DAT-KD mice. In DAT-KO mice, mRNA analysis showed a decrease (~50%) in both D<sub>1</sub>R and D<sub>2</sub>R transcriptions (7), whereas in DAT-KD mice, no difference was found in postsynaptic D<sub>1</sub>R and D<sub>2</sub>R binding although evidence was obtained for ~50% reduction in level of D<sub>2</sub>R autoreceptors (7, 8). Again, such differences are likely related to the nature of the two transgenic mouse models leading to differential changes in DA dynamics and adaptive changes.

The decrease in D<sub>2</sub>R binding observed in the DAT-AAA mice is interesting given that the most commonly observed trait for the addicted brain is a selective decrease in striatal D<sub>2</sub>R availability as a presumed consequence of increased extracellular DA levels in human addicts of cocaine, methamphetamine, alcohol, and heroin (18, 19) as well as obese overeaters (17). These changes in striatal D<sub>2</sub>R levels are observed as well in animals with an increased compulsive behavior toward drugs (38–40) and “fast food” (41). In DAT-AAA mice, we moreover found, as discussed previously, a decreased pool of DA, which is considered another putative biomarker of addiction found in cocaine and heroin-addicted patients (21, 42). Thus, the adaptive changes observed in DAT-AAA mice seem to partially mimic those seen in the brain of addicted individuals.

Our behavioral analysis of the DAT-AAA mice revealed several interesting features. First, we observed that DAT-AAA mice are willing to work harder for a food reward than WT mice. It has been suggested that overeating promoted by high-calorie foods or “fast food” is controlled through the same pathways as those responsible for the rewarding effect of drugs of abuse (43–45) and, thus, that binge eating of palatable food will, similar to drugs of abuse, cause an acute increase in striatal extracellular DA (46). At the same time, lowered D<sub>2</sub>R levels have been associated with accelerated appearance of compulsive-like consumption of palatable food (43–45). Thus, the lowered D<sub>2</sub>R levels combined with higher evoked DA levels in DAT-AAA mice might directly underlie the willingness of the mice to work harder for a food reward than WT mice. Our data are in line with findings on DAT-KD mouse, showing higher food intake in their home cages and an increased wanting of sucrose (47). In contrast, DAT-KO strains showed an unaltered number of days to learn operant behavior for food (48) or no difference in FR5 and PR schedules for 20 mg of food pellets (49), most likely reflecting DA homeostatic differences between mice having no transporter and mice with ~20% of WT uptake capacity as the DAT-AAA mice.

Although DAT-AAA mice worked harder for a food reward as compared with WT mice, they did not show increased willingness to work for a cocaine reward. The most likely explanation is that cocaine's effect is blunted by the dramatically reduced level of DAT leading to a “cocaine-like state” with impaired clearance and elevated DA peak concentrations plus decreased D<sub>2</sub>R levels. In that sense, the data substantiate DAT as a primary target for the stimulatory action of cocaine

in agreement with previous experiments in DAT-KO mice and in mice expressing a DAT variant unable to bind cocaine (DAT-Ci mice), showing complete lack of interest in cocaine self-administration (6, 50, 51). It was, nonetheless, somewhat surprising to find that drug-naïve DAT-AAA mice performed similar to WT mice in a naive acquisition experiment using 1.0 mg/kg/infusion cocaine (Fig. S4). This indicates that DAT-AAA mice can recognize the cocaine dose used as reinforcer in the active nose-poke hole *versus* no reinforcer in the inactive. Indeed, this is also supported by our *in vivo* microdialysis experiments demonstrating that cocaine did cause a modest increase in striatal DA levels in DAT-AAA mice, yet the response was significantly reduced compared with that seen in WT mice.

In conclusion, we present a mouse model with unique presynaptic and postsynaptic adaptations of the DA system that occur as a consequence of disrupting the ability of DAT to bind PDZ domain scaffold proteins to its C terminus and that show interesting resemblance to the changes seen in the addicted brain. The mouse model might accordingly represent an important basis for further investigating the still poorly understood link between molecular alterations, changed DA homeostasis, and compulsive drug or food intake.

## Experimental procedures

### Mice

DAT-AAA mice were generated as previously described (27). Adult male mice were acclimatized to the animal facilities, where experiments were conducted, for at least 1 week prior to experiments in group-housed cages (Macrolon type III cages) and kept on a 12-h light/dark cycle in a temperature-controlled and humidity-controlled room. Food and water were available *ad libitum*. All experiments were conducted during the light phase (8:00 AM–6:00 PM) conducted in accordance with guidelines from the Animal Experimentation Inspectorate, Denmark or in compliance with the Italian Ministry of Health (DL 116/92; DL 111/94B) and European Community (86/609/EEC) directives regulating animal research. All efforts were made to minimize animal suffering and reduce the number of animals used.

### Drugs

Cocaine obtained from HS Pharmacy and quinpirole obtained from Sigma–Aldrich were dissolved in 0.9% saline and prepared immediately before use.

### Super-resolution microscopy

Perfused brains were sliced at 10 μm on a cryostat (Leica CM2050 S) and immediately fused to 18 mm glass coverslips (#1.5) that had been treated with 3-aminopropyl-triethoxysilane (Sigma; 440140). Samples were washed with PBS 3× for 5 min, followed by a combination of glycine (20 mM) and NH<sub>4</sub>Cl (50 mM) in PBS 2× for 15 min. Next, they were washed with PBS 2× for 5 min and subjected to trisodium citrate (Sigma) (10 mM) in distilled water (pH 6.0, heated to 80°) for 30 min. Samples were again washed with PBS 4× for 5 min and

then subject to blocking and permeabilization with 5% donkey serum, 1% bovine serum albumin, and 0.3% Triton X-100 (Sigma) in PBS. Primary antibodies, in blocking and permeabilization buffer, were applied overnight at 4°. DAT MAB369 was used to label DAT (1:200 dilution). VMAT2 was labeled with antibody graciously provided by Dr Gary W. Miller (Columbia University) (1:4000 dilution) (52). The next day, samples were washed with blocking and permeabilization buffer for 5 min, then for increments of 90 min. Secondary antibodies in blocking and permeabilization buffer were applied overnight at 4°. These were applied at concentrations of 10 µg/ml, were bought unlabeled from Jackson ImmunoResearch, and conjugated to Alexa 647 for DAT or to CF568 for VMAT2. The next day, the samples were washed with blocking and permeabilization buffer for 5 min, 5 min, then 90-min increments, followed by PBS 2× for 10 min, paraformaldehyde (PFA) (Electron Microscopy Supplies) (3%) for 15 min, a combination of glycine (20 mM) and NH<sub>4</sub>Cl (50 mM) in PBS 2× for 15 min, and finally stored in PBS at 4° until imaging.

The dSTORM imaging was performed on an ECLIPSE Ti-E epifluorescence/total internal reflection fluorescence microscope (NIKON). Utilizing lasers at 405, 561, and 647 nm, the sample was imaged through a 1.49 numerical aperture ×100 apochromat total internal reflection fluorescence oil immersion objective and a dichroic mirror with the range 350 to 412, 485 to 490, 558 to 564, and 637 to 660 nm (97,335 QUAD C-NSTORM C156921). The emitted light was further filtered by a 561 nm longpass filter (Edge Basic; F76-561; AHF). Data were gathered by an EM-Charge-Coupled Device camera (Andor iXon3 897). The imaging was performed with an imaging buffer containing 10% (w/v) glucose, 1% (v/v) β-mercaptoethanol, 50 mM Tris-HCl (pH 8), 10 mM NaCl, 34 µg ml<sup>-1</sup> catalase, 28 µg ml<sup>-1</sup> glucose oxidase, and 2 mM cyclooctatetraene. Data were collected for 20,000 frames per emission laser, alternating every frame between 561 and 647 nm laser. Each frame was 16 ms. Localization data were obtained and refined through an automatic pipeline. First, localization data were obtained through ThunderSTORM (31). Raw images were subjected to a wavelet filter (B-Spline) with B-Spline order of three and B-Spline scale of two. The method of molecular detection was nonmaximum suppression with a peak intensity threshold of 0.9\*std(Wave.F1) and a dilation radius of three pixels. The resulting data were drift corrected through a Matlab script for redundant cross correlation (53). The localizations were filtered for having an uncertainty value less than 25 nm, and then localizations found within 15 nm and three frames were merged together.

Presynaptic sites were found according to the method defined (29). In brief, the localization data were combined for the VMAT2 signal and DAT signal for each image. The data were subject to a Voronoi tessellation, and shapes larger than a certain size were removed (30). The remaining shapes were merged together, so that those that shared a border were now one shape. Following this merging, small areas were removed. The remaining shapes were smoothed around their edges and used as masks for the dSTORM data, with each shape outlining a likely presynaptic varicosity.

Two different cluster metrics were used for this analysis, each utilizing DBSCAN (33). To compare cluster size, DBSCAN was applied to each varicosity with a search radius of 15 nm and a number of point qualifiers of three localizations. From there, the convex hull was obtained for the localizations in each cluster and the diameter found from approximating the cluster as a circle. The fraction of the clusters with a radius of 75 nm or above was then found for each varicosity. To compare the presence of localizations in dense clusters, DBSCAN was applied to each varicosity with a search radius of 50 nm and a number of point qualifiers of 80 localizations. The fraction of localizations that satisfied these parameters per varicosity was compared.

To identify whether the DAT signal likely resided on the plasma membrane in DA neurons of DAT-AAA mice, the distance from each DAT localization and each VMAT2 localization from the 3D convex hull of its identified varicosity was found for the varicosities in the DAT-AAA dataset. For each varicosity, a 3D convex hull was computed for the combination of DAT and VMAT2 localizations. The distance from every localization was measured to this hull and recorded as to whether it was for DAT or for VMAT2. These distances were compiled into histograms to compare between these molecular targets. There were 610,883 DAT localizations and 580,886 localizations taken from 1186 DAT-AAA varicosities.

To observe whether the single molecule signal for DAT-AAA was legitimate, both WT and DAT-AAA mouse brain slices were stained and imaged for DAT as stated previously, with and without the presence of primary MAB369 antibody targeting DAT.

### **Stereotaxic surgery for microdialysis**

Mice were premedicated with analgesic (Metacam 5 mg/kg s.c.; Boehringer Ingelheim), anesthetized throughout the surgery with sevoflurane (4 v.% sevoflurane in a mixture of 5% CO<sub>2</sub> and 95% O<sub>2</sub>; Baxter), and mounted in a stereotaxic instrument (David Kopf Instruments). During surgery, the eyes of the animal were covered with a neutral eye ointment (Ophta, Rigshospitalets Apotek) for cornea protection. Prior to surgery, DAT-AAA and WT mice were treated with analgesic (Metacam 5 mg/kg s.c.; Boehringer Ingelheim). The middle scalp was removed, and the skull was gently cleaned with artificial cerebrospinal fluid (aCSF) containing 147 mM NaCl, 4 mM KCl, and 2.3 mM CaCl<sub>2</sub>, adjusted to pH 6.5. A small hole ( $d = 1.2$  mm) was drilled, thus allowing intracerebral insertion of a microdialysis guide cannula (CMA7 guide cannula; CMA/Microdialysis AB) into the right dorsal striatum using the following coordinates according to the stereotaxic atlas of Franklin and Paxinos (54): anteroposterior +0.5 mm, mediolateral -2.0 mm relative to bregma, and dorsoventral -3.0 mm relative to skull surface. The microdialysis probe was secured to the skull with an anchor screw and dental acrylic cement (Dentalon Plus; AngThós AB). Animals were then single housed and allowed to recover for 24 h following surgery.



## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes

### Total tissue contents of DA and metabolites

For determination of total tissue contents of DA and metabolites, mice were sacrificed by cervical dislocation, and their brains were immediately taken out and briefly placed on parafilm-covered pulverized dry ice, before striatal tissue was dissected out under microscope (55, 56). Dissected striatal tissues of adult DAT-AAA mice and WT littermates were weighed and homogenized in 500  $\mu$ l 0.1 N perchloric acid saturated with 5% Na<sub>2</sub>EDTA, and samples were quickly placed on crushed ice. Homogenates were then centrifuged at 14,000g for 20 min at 4 °C. Supernatants were filtered through a 0.22  $\mu$ m cellulose acetate microfilter (13CP020AN Advantec; Frisette ApS), and 10  $\mu$ l was subsequently loaded on the HPLC system for further analysis.

### Microdialysis procedure

Microdialysis disposables were obtained from CMA/Microdialysis AB or AgnThós AB. Following recovery from surgery, a CMA/7 microdialysis probe (6000 Da cutoff, CMA/Microdialysis AB; 2 mm dialysis membrane) was under sevoflurane (4 v.% sevoflurane in a mixture of 5% CO<sub>2</sub> and 95% O<sub>2</sub>; Baxter) anesthesia inserted into the guide cannula (57). The microdialysis probe was connected to a microinjection pump by a dual-channel swivel, allowing the conscious animals to move freely during the entire experiment in a bowl (Instech Laboratories). The 2 mm microdialysis probe was perfused at a flow rate of 2.0  $\mu$ l/min for 1 h with aCSF while the animals habituated to baseline. After habituation, the flow rate was switched to 1.8  $\mu$ l/min, and a 20-min sampling regimen was initiated and maintained throughout the experiment using an automated refrigerated fraction collector (CMA 470). Three samples were used to establish DA baseline levels before the animals were injected with cocaine (30 mg/kg s.c.) or saline, and dialysate fractions were collected for 140 min post-treatment. All dialysate fractions were analyzed immediately after collection using reversed-phase HPLC coupled to electrochemical detection. After termination of the microdialysis experiments, mice were sacrificed by cervical dislocation, and brains were quickly removed for probe verification. The brains were cut on a cryostat (Shandon Cryotome), and correct placement of probes was histologically verified under microscope.

### HPLC analysis of monoamines and their metabolites

Briefly, concentrations of DA, DOPAC, HVA, 5-hydroxyindoleacetic acid, and serotonin (5-hydroxytryptamine [5-HT]) in the tissue homogenates and of DA, DOPAC, and HVA in the microdialysis samples were assessed by reversed-phase HPLC coupled to electrochemical detection. The HPLC system consisted of a HPLC pump (LC-20AD; Shimadzu), a degasser (LC-27A; Waters), a Waters refrigerated micro-sampler (SIL-20ACHT; Shimadzu), an amperometric detector (Antec Decade II; Antec), and a computerized data acquisition system (LC Solution, version 1.25; Shimadzu). The electrochemical detector cell was equipped with a glassy carbon electrode operating at +0.7 V *versus* Ag/AgCl reference

electrode. Samples were injected onto a Prodigy C18 column (100 Å ~ 2 mm I.D., particle size of 3  $\mu$ m; Phenomenex). In the tissue homogenates, the monoamines and their metabolites were separated with a mobile phase consisting of 93% of 94.2 mM NaH<sub>2</sub>PO<sub>4</sub>, 0.98 mM octanesulfonic acid, 0.06 mM Na<sub>2</sub>EDTA, adjusted to pH 3.7 with 1 M phosphoric acid and 7% acetonitrile (v/v) at a flow rate of 0.25 ml/min, and detected by a glassy carbon electrode operating at +700 mV *versus* Ag/AgCl reference electrode. The output was recorded, and the area under the curve for each peak was calculated with LC Solution software by Shimadzu. Tissue concentrations of DA, DOPAC, HVA, 5-hydroxyindoleacetic acid, and 5-HT in the samples were estimated using a reference solution containing 0.5 or 1 pmol/sample of all compounds investigated. Concentration of monoamines and metabolites in the homogenate samples were extracted by their area under the curve relative to the area under the curve for the reference compounds, and tissue concentrations were determined relative to the weight of the tissue (microgram/gram tissue). Reference solutions were quantified before each set of homogenates. The limit of detection (at signal-to-noise ratio of 3) for DA was 7 fmol/20  $\mu$ l. In the microdialysis samples, DA and its metabolites were separated with a mobile phase consisting of 55 mM sodium acetate, 1 mM octanesulfonic acid, 0.1 mM Na<sub>2</sub>EDTA, and 8% acetonitrile, adjusted to pH 3.2 with 0.1 M acetic acid. About 10  $\mu$ l of the samples was injected, and the flow rate was 0.25 ml/min.

### FSCV

FSCV experiments were performed as described (9). Briefly, mice were anesthetized with isoflurane and decapitated. The brain was sectioned in cold carboxygenated aCSF (125 mM NaCl, 2.5 mM KCl, 0.3 mM KH<sub>2</sub>PO<sub>4</sub>, 26 mM NaHCO<sub>3</sub>, 2.4 mM CaCl<sub>2</sub>, 10 mM D-glucose, and 1.3 mM MgSO<sub>4</sub>) on a VT1000S vibrating microtome (Leica Microsystems) at a thickness of 300  $\mu$ m. Coronal slices containing the dorsal striatum were allowed to recover for at least 1 h at room temperature in carboxygenated aCSF. For recordings, slices were superfused with 32 °C carboxygenated aCSF at a flow rate of 1 ml/min. Experimental recordings started 20 min after transfer to the slice chamber. Carbon fiber electrodes (5  $\mu$ m; Goodfellow) were made as previously described (58, 59). The carbon fibers were trimmed with a scalpel to 80 to 120  $\mu$ m under a microscope (Nikon). A carbon 301 fiber microelectrode was inserted into the slice, and a twisted bipolar stimulating electrode (Plastics One) was placed on the surface of the brain slice ~200  $\mu$ m away. The potential of the working electrode was held at -0.4 V and scanned to +1.3 V and back at 300 V/s. Axonal DA release in the striatum was evoked by a single biphasic electrical pulse (1 ms long, 400  $\mu$ A) every 2 min through a stimulus isolator (AM Systems).

Data were filtered to reduce noise. Oxidation and reduction peaks were observed at approximately +0.65 V and -0.2 V (*versus* Ag/AgCl reference) identifying DA as the released chemical. Electrodes were calibrated in a flow injection system using 1  $\mu$ M DA (Sigma-Aldrich).

Data were normalized to the first five recordings (10 min) of their respective control period and graphically plotted against time (means  $\pm$  SEM). Data analysis was performed using Demon Voltammetry software described (60). Briefly, computations were based on user-defined positions on current traces for baseline (Pre-Stim cursor), peak (Peak Cursor), and return to baseline (Post-Stim cursor) positions. Half-life values were determined from exponential fit curves based on Peak Cursor and Post-Stim cursor positions using a least square constrained exponential fit algorithm (National Instruments).

### **Autoradiography**

For receptor autoradiography, DAT-AAA and WT mice were decapitated by cervical dislocation; brains were immediately taken out and frozen on dry ice. Brains were then stored at  $-80^{\circ}\text{C}$  until sectioning. Using a cryostat (Shandon Cryotome SME),  $15\ \mu\text{m}$  coronal sections were cut to acquire striatal (1.54–0.74 mm relative to bregma), as well as VTA/SN ( $-3.08\ \text{mm}$  to  $-3.64\ \text{mm}$  relative to bregma) slices for  $\text{D}_1\text{R}$  and  $\text{D}_2\text{R}$  autoradiography. The sections were thaw mounted onto glass slides (Superfrost Plus microscope; Menzel-Gläser), and allowed to dry before storage at  $-80^{\circ}\text{C}$ . While sectioning, orientation in the coronal plane was maintained by referring to a stereotaxic atlas of the mouse brain (54).

For detection of the  $\text{D}_1\text{R}$  with [ $^3\text{H}$ ]SCH23390, glass slides with mounted tissue sections were incubated in preincubation buffer (50 mM Tris base, 120 mM NaCl, 5 mM KCl, 2 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , and 20 nM MDL-100907) at  $0^{\circ}\text{C}$  for 15 min. Application of the 5-HT $_2\text{A}$  antagonist, MDL-100907 (H. Lundbeck), was done to overcome the  $\text{D}_1\text{R}$  radioligand ([ $^3\text{H}$ ]SCH23390) affinity for 5-HT $_2\text{A}$  receptors. Sections were then incubated with a  $\text{D}_1\text{R}$  antagonist for 1 h at  $4^{\circ}\text{C}$  in a solution equivalent to the preincubation buffer with the addition of 1 nM [ $^3\text{H}$ ]SCH23390 (PerkinElmer; 85 Ci/mmol). Nonspecific binding was determined by incubating sections under the same conditions with excess amount of the  $\text{D}_1\text{R}$ ,  $\text{D}_2\text{R}$ , and 5-HT $_2$  receptor antagonist *cis*-(Z)-flupentixol (10  $\mu\text{M}$ ; H. Lundbeck). Sections were then washed for  $2 \times 5$  min in preincubation buffer at  $0^{\circ}\text{C}$  and rinsed in demineralized water. Sections were allowed to dry in a flow bench overnight before they were exposed to Fuji BAS-TR2040 Phosphor imaging plates. Films were then exposed with standard [ $^3\text{H}$ ]-polymer-microscales (batch 19; Amersham Biosciences) for 17 days in autoradiography cassettes at room temperature prior to analysis.

For detection of the  $\text{D}_2\text{R}$  with [ $^3\text{H}$ ]-raclopride, glass slides with mounted tissue sections were incubated in preincubation buffer (50 mM Tris base, 120 mM NaCl, 5 mM KCl, 2 mM  $\text{CaCl}_2$ , and 1 mM  $\text{MgCl}_2$ ) at  $0^{\circ}\text{C}$  for 15 min. Sections were then incubated with a  $\text{D}_2\text{R}$  antagonist for 1 h at  $4^{\circ}\text{C}$  in a solution equivalent to the preincubation buffer with the addition of 4 nM [ $^3\text{H}$ ]raclopride (PerkinElmer; 60.1 Ci/mmol). Nonspecific binding was determined by incubating sections under the same conditions with excess amount of the  $\text{D}_2\text{R}$ , 5-HT $_2\text{R}$ , and  $\alpha_1\text{R}$  antagonist sertindole (10  $\mu\text{M}$ ; H. Lundbeck).

Incubation was followed by a washing phase for  $2 \times 30$  min in preincubation buffer at  $0^{\circ}\text{C}$  in buffer. Sections were allowed to dry in the flow bench overnight before they were exposed to Fuji BAS-TR2040 Phosphor imaging plates. Films were then exposed with standard [ $^3\text{H}$ ]-polymer-microscales (batch 19; Amersham Biosciences) for 17 days in autoradiography cassettes at room temperature prior to analysis.

The Fuji BAS-TR2040 Phosphor imaging plates were read in a STARION FLA-9000 image scanner (Fujifilm Life Science). The emitted radiation stored in the imaging plates was converted to a digital image. Densitometric image analysis of autoradiograms was achieved using WCIF ImageJ software (version 1.37a; the National Institutes of Health) to quantify  $\text{D}_1\text{R}$  and  $\text{D}_2\text{R}$  levels. Regions of interest (dorsal striatum, ventral striatum, and ventral midbrain) were selected for each section, and the mean pixel density in the selected regions was measured. Image density in the selected regions was expressed in arbitrary units as a gray-scale level with a value designated each pixel according to its density. Quantification of receptor binding was achieved by calibrating the pixel density to decay-corrected [ $^3\text{H}$ ]-polymer-microscale activity levels. The calibration allowed for quantification of receptor levels in Bq per milligram tissue instead of arbitrary pixel densities. Levels of receptor binding were measured bilaterally in the dorsal and ventral striatum. Values from both sides (right and left) were averaged for each section and animal. For better visualization, and to acquire higher anatomical resolution of the autoradiograms, exposure to tritium-sensitive films (KODAK Biomax MR; Amersham Biosciences) at  $-20^{\circ}\text{C}$  for 85 days was achieved succeeding phosphoimage exposure. Films were developed in a Kodak GBX film developer and fixer (Sigma-Aldrich).

### **Radioligand binding assay**

Adult mice were sacrificed by decapitation, and brains were rapidly removed. Striata from DAT-AAA and WT mice were dissected from coronal slices and homogenized in ice-cold homogenization buffer (50 mM Tris-HCl, 1 mM EDTA, pH 7.4) using a motor-driven Teflon pestle with ten even strokes at 800 rpm. Homogenate was centrifuged at  $16,000g$  at  $4^{\circ}\text{C}$  for 30 min to isolate the membrane fraction. Membranes were resuspended in ice-cold binding buffer (25 mM Hepes, 120 mM NaCl, 5 mM KCl, 1.2 mM  $\text{CaCl}_2$ , 1.2 mM  $\text{MgSO}_4$ , 1 mM L-ascorbic acid, 5 mM D-glucose, and pH 7.4) followed by assessment of protein concentration using BCA Protein Assay kit (Pierce). Saturation binding experiments were performed on striatal membrane preparations using various concentrations of  $^3\text{H}$ -raclopride, a  $\text{D}_2\text{R}$  antagonist (71.3 Ci/mmol; PerkinElmer). For determination of nonspecific binding, quinpirole hydrochloride (0.3 mM), a  $\text{D}_2\text{R}$  agonist, was included. Membrane suspensions (final incubation, 0.3–0.4 mg protein/ml) were mixed with  $^3\text{H}$ -raclopride in binding buffer (a total volume of 500  $\mu\text{l}$ ) containing 25 mM Hepes, pH 7.4, 120 mM NaCl, 5 mM KCl, 1.2 mM  $\text{CaCl}_2$ , and 1.2 mM  $\text{MgSO}_4$  for 1 h at room temperature with constant shaking. Membranes were then immediately loaded on glass

## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes

microfiber filters (GF/C Whatman), rinsed 2 × 8 ml in ice-cold binding buffer, and allowed to air dry. Scintillation fluid was added, and filters were agitated for 1 h and counted in Wallac Tri-Lux β-scintillation counter (PerkinElmer). Binding data were analyzed by nonlinear regression analysis assuming one-site binding (GraphPad Prism 5.0; GraphPad Software, Inc).

### Real-time qRT-PCR

Mouse brain samples were obtained from age-matched WT and DAT-AAA mice (WT, n = 6, all males; KI, n = 6, five males and one female). Brains were stored at -80 °C until use. Tools and surfaces were treated with 70% ethanol and/or RNaseZap Solution (Thermo Fisher Scientific) to prevent RNase activity before isolation of tissue samples. Brain slices were isolated using a brain matrix, and striatal samples were isolated using a puncher, whereas midbrain and cerebellum samples were obtained by microdissection. Samples were placed in 1 ml QIAzol Lysis Reagent (Qiagen) and then transferred to a 1 ml Wheaton glass homogenizer tube and homogenized by a motor-driven Teflon homogenizer at 900 rpm at high-speed function using 20 strokes. Homogenization and lysis were completed by passing the homogenates five times through a 21G needle. Automated RNA extraction was performed by utilizing RNeasy Lipid Tissue Mini Kit (Qiagen) on a semiautomated QIAcube Connect (Qiagen) according to the manufacturer's instructions. RT was performed with Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) using 1 µg/µl of RNA from each sample. The resulting complementary DNA (20 µl reaction) was further diluted with 250 µl EB buffer (Qiagen) and then pipetted onto a 384-well plate (0.4 µl per well) previously loaded with 2 µl/well of Sybr green Mastermix (Roche Life Science) and 1.6 µl/well of primer solution (forward and reverse primers, 0.95 µM). The reaction mixture (total 4 µl per well) was mixed using a contactless liquid handler (I-DOT; Immediate Drop-On-Demand Technology; Dispensix). Specific primers for target genes and two housekeeping genes, *Gapdh* and *Yhwaz*, were designed and validated prior to the experiment. The primer sequences were as follows: *Drd1*: forward, TCT CCC AGA TCG GGC ATT, reverse, GTC ACT TTT CGG GGA TGC TG; *Drd2*: forward, TCG TCA CCC TGC TGG TCT AT, reverse, TGG GTA CAG TTG CCC TTG AGT; *Yhwaz*: forward, GAA GCA TTG GGG ATC AAG AA, reverse, AGA CGG AAG GTG CTG AGA AA; and *Gapdh*: forward, AAG GGC TCA TGA CCA CAG TC, reverse, GGA TGC AGG GAT GAT GTT CT. Primer efficiency was ascertained through a seven-step dilution curve. qRT-PCR was performed on a LightCycler 480 II instrument (Roche Life Science), using a customized protocol: 10 min of denaturation at 95 °C, followed by 40 cycles of 15 s at 95 °C and 30 s acquisition at 60 °C, terminated with a melting curve. The corresponding Ct value for each well was calculated using the on-board software (Roche), with a maximum cutoff of 35 cycles. For each independent experiment, samples were run in technical triplicates, and averaged Ct values were used for all calculations. Fold change in relative expression levels was

determined by utilizing the fold change =  $2^{-(\Delta\Delta Ct)}$  method as suggested by Livak and Schmittgen (61). Relative expression was calculated as the average fold change relative to cerebellum, using two housekeeping genes *Gapdh* and *Yhwaz* as internal controls. Cerebellum serves as a control tissue confirming that the experimental setup was able to detect tissue-specific variation in D<sub>1</sub>R and D<sub>2</sub>R transcriptions.

### Immunohistochemistry

Adult mice were anesthetized and transcardially perfused with heparinized PBS followed by 4% PFA in 0.1 M PBS. The brains were isolated, postfixed in PFA for 24 h, and transferred to 20% sucrose for cryoprotection. Brains were then rapidly frozen on powdered dry ice and kept at -80 °C until further processing. Subsequently, coronal sections (40 µm) from striatum and midbrain were generated and stored in antifreeze solution at -20 °C. For bright-field immunohistochemistry, a standard peroxidase-based method using 3,3'-diaminobenzidine was applied. Free-floating tissue sections were rinsed in PBS three times followed by preincubation with 5% rabbit serum in PBS containing 0.3% Triton X-100 and 1% bovine serum albumin. Sections were then incubated with rat polyclonal D<sub>1</sub>R antibody (1:1000; Sigma-Aldrich) at 4 °C overnight. On the second day, sections were rinsed and incubated with biotinylated rabbit anti-rat IgG for 1 h (1:200; DAKO Cytomation A/S). Following avidin-biotin-peroxidase complex (Vector Laboratories) incubation, peroxidase was visualized using 3,3'-diaminobenzidine (0.5 mg/ml) and 0.01% H<sub>2</sub>O<sub>2</sub> treatment. After additional washing, sections were mounted on SuperFrost slides (Menzel-Gläser), air dried overnight, and finally coverslipped using Pertex (Histolab).

### Operant behavior

Intravenous self-administration equipment, training, and evaluation procedures were previously described (62). In short, the operant chambers (Med Associates) contained two nose-poke holes 10 mm above the grid floor, both equipped with photocells and a discriminative cue light, positioned on either side of a small dish-shaped plate into which liquid food could be delivered. Responding in the right hole resulted in delivery of a reinforcer and illumination of the cue light for 20 s, during which additional responses were counted but had no scheduled consequences (timeout responses).

### Catheter implantation surgery and maintenance

Under isoflurane vapor anesthesia, a catheter (SILASTIC tubing; inner diameter of 0.18 mm, outer diameter of 0.41 mm; CamCaths) was inserted 1.2 cm into the right or left jugular vein and anchored to the vein with sutures. The catheter ran subcutaneously to the base located above the midscapular region. During the subsequent 7 days of postsurgical recovery, 0.02 ml of 0.9% saline containing heparin (30 U/ml; SAD) and antibiotic (cefazolin; 50 mg/ml; Hexal) was infused daily through the catheter to prevent clotting and infection.



Catheter patency was confirmed 7 days after surgery and after completion of each experimental phase by the loss of muscle tone and clear signs of anesthesia within 3 s after infusion of 0.02 to 0.03 ml ketamine (15 mg/ml; Pfizer) and midazolam (0.75 mg/ml; Matrix Pharmaceuticals) in saline.

#### **Liquid food self-administration under an FR schedule**

A separate set of experimentally naive mice was used for self-administration of a nondrug reinforcer under an FR schedule. The mice were mildly food deprived before the first presentation of liquid food (5 ml of Nutridrink high-energy drink, vanilla flavor; Nutricia A/S) in the operant chamber (*i.e.*, *ad libitum* dry food in the home cage was removed 18–20 h before the session, water remained available). When  $\geq 1.5$  ml of the 5 ml available was consumed per 2-h session, mice were placed in the operant chamber with one active and one inactive nose-poke hole for daily 2-h sessions similar to cocaine FR1 self-administration. Acquisition lasted for at least five consecutive sessions and until criteria were met ( $\geq 20$  reinforcers earned, with  $\leq 20\%$  variation over two consecutive sessions and  $\geq 70\%$  responses in the active hole). Subsequently, water was substituted for at least three sessions and until responding was extinguished to  $< 80\%$  of food-maintained responding. Then, a range of liquid food dilutions (Nutridrink: water; 3%, 10%, 32%, and 100%) was presented according to a Latin-square design, determined twice in each mouse.

#### **Cocaine self-administration and liquid food-maintained behavior under a PR schedule**

After FR1 schedule, mice proceeded with cocaine self-administration under a PR schedule of reinforcement. Mice that had self-administered liquid food under a FR1 schedule proceeded in a similar PR schedule with liquid food as the reinforcer. After stable responding under the FR1 schedule maintained by cocaine (1.0 mg/kg/infusion) or undiluted food, an FR3 schedule was used as a transition from the FR1 schedule before introducing the PR schedule. For the PR schedule, the starting ratio was 3 and then increased by 0.115 log units after each reinforcer delivery (*i.e.*, 3, 4, 6, 7, 10, 13, 16, 21, 28, 36 ...). The breaking point was defined as the step value associated with the last completed ratio (*i.e.*, number of reinforcers earned) after a limited hold of 60 min (*i.e.*, period with no reinforcer earned). If a breaking point was not reached within 6 h, the session was terminated to prevent health hazard, and the last reached ratio was used. After stable baseline was achieved (two consecutive sessions with breaking points  $> 5$  and with  $< 20\%$  variation), saline or water was substituted until responding extinguished to  $\leq 50\%$  of the baseline breaking point. Cocaine dose–effect curves (0.1, 0.32, 1.0, and 3.2 mg/kg/infusion cocaine) and liquid food concentration–effect curves (0%, 3%, 10%, 32%, and 100% food in water) were determined according to a Latin-square design, with each dose tested for two or three consecutive sessions (*i.e.*, if the breaking points reached in the two first determinations varied by  $> 20\%$ , a third determination was made).

#### **Drug-induced locomotion**

Locomotor activity was measured in monitoring frames equipped with eight horizontal infrared light beams along the long axis of the frame placed 4.3 cm apart and 3.3 cm above the surface as previously described (27, 63). Standard cages (Macrolon type III;  $37 \times 21 \times 17$  cm) with a lining of fresh wood-chip bedding were placed in the monitoring frames and covered with Plexiglas tops with ventilation holes. The setup was situated in a ventilated room. A computer program (MOTM; Ellegaard Systems) recorded interruptions of the infrared light beams as counts of beam breaks in intervals of 5 min. Cages were cleaned between tests. Mice were injected with cocaine or saline *i.p.* 3 to 7 min before testing. The animals were then placed in a cage, and the activity was measured for 1 h.

#### **Statistics**

All statistical analyses were performed using GraphPad Prism 8 or 9 ([www.graphpad.com](http://www.graphpad.com)). Two-way ANOVA was used together with Holm–Sidak post hoc test for analysis of DA and DA metabolite tissue content, food, and cocaine self-administration and cocaine-induced locomotor activity data. A three-way repeated-measures ANOVA was used together with Holm–Sidak post hoc test for analysis of microdialysis data. DA receptor binding data (autoradiography) were analyzed by use of multiple *t* testing with Holm–Sidak correction, whereas [ $^3\text{H}$ ]-raclopride binding ( $B_{\text{max}}$ ) was analyzed by a one-sample *t* test. FSCV data and super-resolution microscopy data were analyzed by unpaired *t* tests or Wilcoxon matched-pairs signed rank test. The qRT–PCR data were analyzed by nonparametric Mann–Whitney test. Significance level was set at  $p < 0.05$  in all analyses. Data are shown as mean  $\pm$  SE.

#### **Data availability**

All data relating to this article are contained in the article.

*Supporting information*—This article contains supporting information.

*Acknowledgments*—We thank Pia Elsmann, Birgit Hansen, Saiy Kirsari, and Pernille Clausen for excellent technical assistance.

*Author contributions*—G. S., D. W., R. R. G., A. F.-J., and U. G. conceptualization; D. L., G. S., M. R., M. D. L., P. H. R., P. W., J. H. L., P. R., F. H., G. W., and R. R. G. methodology; M. D. L. software; G. S., M. R., D. L., P. W., F. H., D. W., R. R. G., and A. F.-J. validation; G. S., M. R., D. L., M. D. L., P. W., G. W., R. R. G., and U. G. formal analysis; G. S., M. R., D. L., M. D. L., P. H. R., P. W., J. H. L., F. H., D. W., and A. F.-J. investigation; R. R. G., A. F.-J., and U. G. resources; G. S., M. R., D. L., M. D. L., G. W., and U. G. data curation; G. S. and U. G. writing—original draft; U. G. writing—review and editing; G. S., M. D. L., P. W., F. H., and U. G. visualization; G. S., M. R., P. R., F. H., D. W., G. W., A. F.-J., and U. G. supervision; M. R. and U. G. project administration; U. G. funding acquisition.

*Funding and additional information*—The work was supported by the University of Copenhagen BioScaRT Program of Excellence (to

## DAT-AAA mice: nanoscopic, homeostatic and behavioral changes

G. S., D. W., G. W., A. F.-J., and U. G.), the National Institutes of Health grants P01 DA 12408 (to U. G.), Independent Research Fund Denmark—Medical Sciences (4004-00097B to U. G.), Lundbeck Foundation R199-2015-2110 and R77-2010-6815 (to U. G. and M. R.), the Novo Nordisk Foundation (NNF16OC0023104) (to U. G.), and St. Petersburg State University, St. Petersburg, Russia (project ID: 51143531) (to R. R. G.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**Conflict of interest**—The authors declare that they have no conflicts of interest with the contents of this article.

**Abbreviations**—The abbreviations used are: 5-HT, 5-hydroxytryptamine; aCSF, artificial cerebrospinal fluid; D<sub>1</sub>R, D1 receptor; D<sub>1</sub>R-ir, D1R-immunoreactivity; D<sub>2</sub>R, D2 receptor; DA, dopamine; DAT, dopamine transporter; DBSCAN, density-based spatial clustering of applications with noise; DOPAC, 3,4-dihydroxyphenylacetic acid; dSTORM, direct stochastic reconstruction microscopy; FR1, fixed ratio of one; FSCV, fast-scan cyclic voltametry; HVA, homovanillic acid; KD, knockdown; KI, knock-in; PFA, paraformaldehyde; PR, progressive ratio; qRT-PCR, quantitative RT-PCR; s.c., subcutaneously; VMAT2, vesicular monoamine amine transporter 2; VTA, ventral tegmental area.

### References

1. German, C. L., Baladi, M. G., McFadden, L. M., Hanson, G. R., and Fleckenstein, A. E. (2015) Regulation of the dopamine and vesicular monoamine transporters: Pharmacological targets and implications for disease. *Pharmacol. Rev.* **67**, 1005–1024
2. Iversen, S. D., and Iversen, L. L. (2007) Dopamine: 50 years in perspective. *Trends Neurosci.* **30**, 188–193
3. Tritsch, N. X., and Sabatini, B. L. (2012) Dopaminergic modulation of synaptic transmission in cortex and striatum. *Neuron* **76**, 33–50
4. Kristensen, A. S., Andersen, J., Jorgensen, T. N., Sorensen, L., Eriksen, J., Loland, C. J., Stromgaard, K., and Gether, U. (2011) SLC6 neurotransmitter transporters: Structure, function, and regulation. *Pharmacol. Rev.* **63**, 585–640
5. Gainetdinov, R. R., and Caron, M. G. (2003) Monoamine transporters: From genes to behavior. *Annu. Rev. Pharmacol. Toxicol.* **43**, 261–284
6. Chen, R., Tilley, M. R., Wei, H., Zhou, F., Zhou, F. M., Ching, S., Quan, N., Stephens, R. L., Hill, E. R., Nottoli, T., Han, D. D., and Gu, H. H. (2006) Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. *Proc. Natl. Acad. Sci. U. S. A.* **103**, 9333–9338
7. Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., and Caron, M. G. (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. *Nature* **379**, 606–612
8. Zhuang, X., Oosting, R. S., Jones, S. R., Gainetdinov, R. R., Miller, G. W., Caron, M. G., and Hen, R. (2001) Hyperactivity and impaired response habituation in hyperdopaminergic mice. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 1982–1987
9. Leo, D., Sukhanov, I., Zoratto, F., Illiano, P., Caffino, L., Sanna, F., Messa, G., Emanuele, M., Esposito, A., Dorofeikova, M., Budygin, E. A., Mus, L., Efimova, E. V., Niello, M., Espinoza, S., et al. (2018) Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats. *J. Neurosci.* **38**, 1959–1972
10. Jaber, M., Dumartin, B., Sagne, C., Haycock, J. W., Roubert, C., Giros, B., Bloch, B., and Caron, M. G. (1999) Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. *Eur. J. Neurosci.* **11**, 3499–3511
11. Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., and Caron, M. G. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. *Proc. Natl. Acad. Sci. U. S. A.* **95**, 4029–4034
12. DiCarlo, G. E., Aguilar, J. I., Matthies, H. J., Harrison, F. E., Bundschuh, K. E., West, A., Hashemi, P., Herborg, F., Rickhag, M., Chen, H., Gether, U., Wallace, M. T., and Galli, A. (2019) Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors. *J. Clin. Invest.* **129**, 3407–3419
13. Mergy, M. A., Gowrishankar, R., Gresch, P. J., Gantz, S. C., Williams, J., Davis, G. L., Wheeler, C. A., Stanwood, G. D., Hahn, M. K., and Blakely, R. D. (2014) The rare DAT coding variant Val559 perturbs DA neuron function, changes behavior, and alters *in vivo* responses to psychostimulants. *Proc. Natl. Acad. Sci. U. S. A.* **111**, E4779–4788
14. Volkow, N. D., and Morales, M. (2015) The brain on drugs: From reward to addiction. *Cell* **162**, 712–725
15. Brody, A. L., Olmstead, R. E., London, E. D., Farahi, J., Meyer, J. H., Grossman, P., Lee, G. S., Huang, J., Hahn, E. L., and Mandelkern, M. A. (2004) Smoking-induced ventral striatum dopamine release. *Am. J. Psychiatry* **161**, 1211–1218
16. Hietala, J., West, C., Syvalahti, E., Nagren, K., Lehtikoinen, P., Sonninen, P., and Ruotsalainen, U. (1994) Striatal D2 dopamine receptor binding characteristics *in vivo* in patients with alcohol dependence. *Psychopharmacology (Berl.)* **116**, 285–290
17. Volkow, N. D., Wang, G. J., Telang, F., Fowler, J. S., Thanos, P. K., Logan, J., Alexoff, D., Ding, Y. S., Wong, C., Ma, Y., and Pradhan, K. (2008) Low dopamine striatal D2 receptors are associated with prefrontal metabolism in obese subjects: Possible contributing factors. *Neuroimage* **42**, 1537–1543
18. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Ding, Y. S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., Gifford, A., Wong, C., and Pappas, N. (2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: Association with metabolism in the orbitofrontal cortex. *Am. J. Psychiatry* **158**, 2015–2021
19. Martinez, D., Saccone, P. A., Liu, F., Slifstein, M., Orlowska, D., Grassetti, A., Cook, S., Broft, A., Van Heertum, R., and Comer, S. D. (2012) Deficits in dopamine D(2) receptors and presynaptic dopamine in heroin dependence: Commonalities and differences with other types of addiction. *Biol. Psychiatry* **71**, 192–198
20. Martinez, D., Gil, R., Slifstein, M., Hwang, D. R., Huang, Y., Perez, A., Kegeles, L., Talbot, P., Evans, S., Krystal, J., Laruelle, M., and Abi-Dargham, A. (2005) Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. *Biol. Psychiatry* **58**, 779–786
21. Martinez, D., Greene, K., Broft, A., Kumar, D., Liu, F., Narendran, R., Slifstein, M., Van Heertum, R., and Kleber, H. D. (2009) Lower level of endogenous dopamine in patients with cocaine dependence: Findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. *Am. J. Psychiatry* **166**, 1170–1177
22. Volkow, N. D., Fowler, J. S., Wang, G. J., Hitzemann, R., Logan, J., Schlyer, D. J., Dewey, S. L., and Wolf, A. P. (1993) Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. *Synapse* **14**, 169–177
23. Wang, G. J., Smith, L., Volkow, N. D., Telang, F., Logan, J., Tomasi, D., Wong, C. T., Hoffman, W., Jayne, M., Alia-Klein, N., Thanos, P., and Fowler, J. S. (2012) Decreased dopamine activity predicts relapse in methamphetamine abusers. *Mol. Psychiatry* **17**, 918–925
24. Ashok, A. H., Mizuno, Y., Volkow, N. D., and Howes, O. D. (2017) Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: A systematic review and meta-analysis. *JAMA Psychiatry* **74**, 511–519
25. Nutt, D. J., Lingford-Hughes, A., Erritzoe, D., and Stokes, P. R. (2015) The dopamine theory of addiction: 40 years of highs and lows. *Nat. Rev. Neurosci.* **16**, 305–312
26. Trifilieff, P., and Martinez, D. (2014) Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity. *Neuropharmacology* **76 Pt B**, 498–509
27. Rickhag, M., Hansen, F. H., Sorensen, G., Strandfelt, K. N., Andresen, B., Gotfryd, K., Madsen, K. L., Vestergaard-Klewe, I., Ammendrup-Johnsen, I., Eriksen, J., Newman, A. H., Fuchtbauer, E. M., Gomez, J., Woldbye, D. P., Wortwein, G., et al. (2013) A C-terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter. *Nat. Commun.* **4**, 1580

28. Rahbek-Clemmensen, T., Lycas, M. D., Erlendsson, S., Eriksen, J., Apuschkin, M., Vilhardt, F., Jørgensen, T. N., Hansen, F. H., and Gether, U. (2017) Super-resolution microscopy reveals functional organization of dopamine transporters into cholesterol and neuronal activity-dependent nanodomains. *Nat. Commun.* **8**, 740
29. [preprint] Lycas, M. D., Ejdrup, A. L., Sørensen, A. T., Haarh, N. O., Jørgensen, S. H., Guthrie, D. A., Götz, R., Stoier, J. F., Werner, C., Newman, A. H., Sauer, M., Herborg, F., and Gether, U. (2020) Nanoscopic dopamine transporter distribution and conformation are inversely regulated by excitatory drive and D2-autoreceptor activity. *bioRxiv*. <https://doi.org/10.1101/2021.03.09.434538>
30. Levet, F., Hosy, E., Kechkar, A., Butler, C., Beghin, A., Choquet, D., and Sibarita, J. B. (2015) SR-tesseler: A method to segment and quantify localization-based super-resolution microscopy data. *Nat. Methods* **12**, 1065–1071
31. Ovesny, M., Krizek, P., Borkovec, J., Svindrych, Z., and Hagen, G. M. (2014) ThunderSTORM: A comprehensive ImageJ plug-in for PALM and STORM data analysis and super-resolution imaging. *Bioinformatics* **30**, 2389–2390
32. Block, E. R., Nuttle, J., Balcita-Pedicino, J. J., Caltagareone, J., Watkins, S. C., Sesack, S. R., and Sorkin, A. (2015) Brain region-specific trafficking of the dopamine transporter. *J. Neurosci.* **35**, 12845–12858
33. Ester, M., Kriegel, H.-P., Sander, J., and Xu, X. (1996) A density-based algorithm for discovering clusters in large spatial databases with noise. In *Proc. 2nd International Conference on Knowledge Discovery and Data Mining*, AAAI Press, United states, 226–231
34. Levey, A. I., Hersch, S. M., Rye, D. B., Sunahara, R. K., Niznik, H. B., Kitt, C. A., Price, D. L., Maggio, R., Brann, M. R., and Ciliax, B. J. (1993) Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. *Proc. Natl. Acad. Sci. U. S. A.* **90**, 8861–8865
35. Choquet, D., and Hosy, E. (2020) AMPA receptor nanoscale dynamic organization and synaptic plasticities. *Curr. Opin. Neurobiol.* **63**, 137–145
36. Cremona, M. L., Matthies, H. J., Pau, K., Bowton, E., Speed, N., Lute, B. J., Anderson, M., Sen, N., Robertson, S. D., Vaughan, R. A., Rothman, J. E., Galli, A., Javitch, J. A., and Yamamoto, A. (2011) Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. *Nat. Neurosci.* **14**, 469–477
37. Marcellino, D., Kehr, J., Agnati, L. F., and Fuxe, K. (2012) Increased affinity of dopamine for D(2) -like versus D(1) -like receptors. Relevance for volume transmission in interpreting PET findings. *Synapse* **66**, 196–203
38. Flagel, S. B., Chaudhury, S., Waselus, M., Kelly, R., Sewani, S., Clinton, S. M., Thompson, R. C., Watson, S. J., Jr., and Akil, H. (2016) Genetic background and epigenetic modifications in the core of the nucleus accumbens predict addiction-like behavior in a rat model. *Proc. Natl. Acad. Sci. U. S. A.* **113**, E2861–E2870
39. Nader, M. A., Morgan, D., Gage, H. D., Nader, S. H., Calhoun, T. L., Buchheimer, N., Ehrenkauf, R., and Mach, R. H. (2006) PET imaging of dopamine D2 receptors during chronic cocaine self-administration in monkeys. *Nat. Neurosci.* **9**, 1050–1056
40. Nader, M. A., Czoty, P. W., Gould, R. W., and Riddick, N. V. (2008) Review. Positron emission tomography imaging studies of dopamine receptors in primate models of addiction. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **363**, 3223–3232
41. Johnson, P. M., and Kenny, P. J. (2010) Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. *Nat. Neurosci.* **13**, 635–641
42. Volkow, N. D., Fowler, J. S., and Wang, G. J. (1999) Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. *J. Psychopharmacol.* **13**, 337–345
43. Kenny, P. J. (2011) Common cellular and molecular mechanisms in obesity and drug addiction. *Nat. Rev. Neurosci.* **12**, 638–651
44. Kenny, P. J., Voren, G., and Johnson, P. M. (2013) Dopamine D2 receptors and striatopallidal transmission in addiction and obesity. *Curr. Opin. Neurobiol.* **23**, 535–538
45. Volkow, N. D., Wang, G. J., Fowler, J. S., Tomasi, D., and Telang, F. (2011) Addiction: Beyond dopamine reward circuitry. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 15037–15042
46. Wang, G. J., Geliebter, A., Volkow, N. D., Telang, F. W., Logan, J., Jayne, M. C., Galanti, K., Selig, P. A., Han, H., Zhu, W., Wong, C. T., and Fowler, J. S. (2011) Enhanced striatal dopamine release during food stimulation in binge eating disorder. *Obesity (Silver Spring)* **19**, 1601–1608
47. Pecina, S., Cagniard, B., Berridge, K. C., Aldridge, J. W., and Zhuang, X. (2003) Hyperdopaminergic mutant mice have higher “wanting” but not “liking” for sweet rewards. *J. Neurosci.* **23**, 9395–9402
48. Rocha, B. A., Fumagalli, F., Gainetdinov, R. R., Jones, S. R., Ator, R., Giros, B., Miller, G. W., and Caron, M. G. (1998) Cocaine self-administration in dopamine-transporter knockout mice [see comments] [published erratum appears in *Nat Neurosci* 1998 Aug;1(4):330]. *Nat. Neurosci.* **1**, 132–137
49. Hironaka, N., Ikeda, K., Sora, I., Uhl, G. R., and Niki, H. (2004) Food-reinforced operant behavior in dopamine transporter knockout mice: Enhanced resistance to extinction. *Ann. N. Y. Acad. Sci.* **1025**, 140–145
50. Thomsen, M., Hall, F. S., Uhl, G. R., and Caine, S. B. (2009) Dramatically decreased cocaine self-administration in dopamine but not serotonin transporter knock-out mice. *J. Neurosci.* **29**, 1087–1092
51. Thomsen, M., Han, D. D., Gu, H. H., and Caine, S. B. (2009) Lack of cocaine self-administration in mice expressing a cocaine-insensitive dopamine transporter. *J. Pharmacol. Exp. Ther.* **331**, 204–211
52. Cliburn, R. A., Dunn, A. R., Stout, K. A., Hoffman, C. A., Lohr, K. M., Bernstein, A. I., Winokur, E. J., Burkett, J., Schmitz, Y., Caudle, W. M., and Miller, G. W. (2017) Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain. *J. Chem. Neuroanat.* **83–84**, 82–90
53. Wang, Y., Schnitzbauer, J., Hu, Z., Li, X., Cheng, Y., Huang, Z. L., and Huang, B. (2014) Localization events-based sample drift correction for localization microscopy with redundant cross-correlation algorithm. *Opt. Express* **22**, 15982–15991
54. Franklin, K. J. B., and Paxinos, G. (1997) *The Mouse Brain in Stereotaxic Coordinates*, Academic Press, New York, NY
55. Jensen, K. L., Runegaard, A. H., Weikop, P., Gether, U., and Rickhag, M. (2017) Assessment of dopaminergic homeostasis in mice by use of high-performance liquid chromatography analysis and synaptosomal dopamine uptake. *J. Vis. Exp.* <https://doi.org/10.3791/56093>
56. Runegaard, A. H., Jensen, K. L., Fitzpatrick, C. M., Dencker, D., Weikop, P., Gether, U., and Rickhag, M. (2017) Preserved dopaminergic homeostasis and dopamine-related behaviour in hemizygous TH-Cre mice. *Eur. J. Neurosci.* **45**, 121–128
57. Weikop, P., Kehr, J., and Scheel-Kruger, J. (2007) Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: The role of 5-HT1A receptors. *J. Psychopharmacol.* **21**, 795–804
58. Kawagoe, K. T., Zimmerman, J. B., and Wightman, R. M. (1993) Principles of voltammetry and microelectrode surface states. *J. Neurosci. Methods* **48**, 225–240
59. Kuhr, W. G., and Wightman, R. M. (1986) Real-time measurement of dopamine release in rat brain. *Brain Res.* **381**, 168–171
60. Yorgason, J. T., España, R. A., and Jones, S. R. (2011) Demon voltammetry and analysis software: analysis of cocaine-induced alterations in dopamine signaling using multiple kinetic measures. *Neurosci Methods* **202**, 158–164
61. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* **25**, 402–408
62. Schmidt, L. S., Thomsen, M., Weikop, P., Dencker, D., Wess, J., Woldbye, D. P., Wortwein, G., and Fink-Jensen, A. (2011) Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice. *Psychopharmacology (Berl.)* **216**, 367–378
63. Sorensen, G., Jensen, M., Weikop, P., Dencker, D., Christiansen, S. H., Loland, C. J., Bengtsen, C. H., Petersen, J. H., Fink-Jensen, A., Wortwein, G., and Woldbye, D. P. (2012) Neuropeptide Y Y5 receptor antagonism attenuates cocaine-induced effects in mice. *Psychopharmacology (Berl.)* **222**, 565–577